Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ameziane N, Behourah Z, Aida M, Ahed Messaoud M, Bousahba A,
Keywords: GEP-NET, Somatostatin analogs, anti proliferative action, anti secretory action, Management real world practice,
#3056 Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids
Introduction: Molecular characterizations of neuroendocrine neoplasm (NENs) have unveiled candidate alterations associated with aggressiveness and suggested that the molecular link between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) might be subtler than initially thought. For example, we have recently unveiled a new entity of pulmonary carcinoids (supra-carcinoids) with carcinoid-like morphology yet the molecular and clinical features of large cell neuroendocrine carcinoma (LCNEC). Testing hypotheses to explain aggressiveness and the possibility of progression or transition from NET to NEC through the accumulation of genetic anomalies requires in vitro and in vivo experimental models.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Foll M
Authors: Alcala N, Dayton T, Mangiante L, Delhomme T, Tabone-Egling S,
Keywords: organoids, omics, evolution, lung, pancreas, bioinformatics,
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Clement D
Authors: Clement D, Naghibi M, Khan M, Tesselaar M, Verbeek W,
Keywords: total parenteral nutrition, short bowel syndrome, inoperable small bowel obstruction, neuroendocrine tumour,
Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Suh M, Cheon G, Lee D,
Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,